A substantial proportion of diabetes-related foot ulcers fail to close within 12 weeks despite competent standard care — offloading, sharp debridement, infection control, and attention to perfusion. For those wounds, clinicians increasingly turn to adjunctive wound products: bioengineered skin substitutes, placental membrane allografts, and dressings designed to modify the biochemistry of the wound bed. These products are expensive and unevenly evidenced, and understanding what the trial data demonstrate — and what they do not — is essential to using them rationally.
What Counts as an Advanced Wound Product
The category is broad and the terminology inconsistent. Skin substitutes and tissue replacements include bioengineered living cell constructs, acellular dermal matrices, autografts, human allografts, and xenografts of animal origin. Placental-derived products — dehydrated human amnion and chorion allografts — form a related but distinct group, supplying extracellular matrix proteins, cytokines, and growth factors rather than durable skin. Separately, some conventional-format dressings act pharmacologically on the wound bed; the sucrose octasulfate (TLC-NOSF) dressing is the best-studied example.
Skin Substitutes and Tissue Replacement
The Cochrane review by Santema, Poyck, and Ubbink pooled 17 randomised trials involving 1,655 participants and found that skin grafts and tissue replacements, added to standard care, increased ulcer healing rates compared with standard care alone (risk ratio 1.55, 95% CI 1.30–1.85), with a small reduction in amputations across the two trials reporting that outcome. The authors graded the evidence as low quality and made two observations that remain relevant: effect sizes varied enormously between individual products, and 15 of 17 studies involved industry funding or industry-affiliated authors. Where trials compared two products head to head, no specific graft demonstrated superiority over another.
A later systematic review and meta-analysis by Gordon and colleagues, drawing on 25 trials assessing closure at 12 weeks, reported that ulcers treated with biologic skin substitutes were 1.67 times more likely to be closed at 12 weeks and 2.81 times more likely to be closed at 6 weeks than those treated with standard dressings. The direction of effect is consistent; the certainty of the estimate is limited by the same methodological constraints Cochrane identified.
Newer autologous approaches continue to be tested. A multicentre randomised trial reported by Armstrong and colleagues, examining an autologous heterogeneous skin construct in 100 patients with Wagner grade 1 ulcers, found 12-week closure in 70% of treated wounds versus 34% under standard care, with most participants requiring only a single application.
Placental Membrane Allografts
Amniotic and chorionic membrane products have accumulated their own trial base. A 2022 systematic review and meta-analysis by Mohammed and colleagues pooled 11 randomised trials of dehydrated human amnion and chorion allograft added to standard wound care. Complete healing favoured the allograft at both 6 weeks (RR 3.78, 95% CI 2.51–5.70) and 12 weeks (RR 2.00, 95% CI 1.67–2.39), with a mean reduction in healing time of roughly 12 days at 12 weeks. An earlier systematic review by Lakmal and colleagues reached a similar conclusion while emphasising the heterogeneity of membrane preparation methods and endpoint definitions across studies.
Sucrose Octasulfate Dressings
The Explorer trial remains the methodologically strongest study of a wound-bed-modifying dressing in this population. Edmonds and colleagues randomised 240 patients with non-infected neuroischaemic ulcers across 43 European diabetic foot clinics to a sucrose octasulfate dressing or an identical dressing without the active agent, double-blind, over 20 weeks. Wound closure occurred in 48% of the treatment group versus 30% of controls (adjusted odds ratio 2.60, 95% CI 1.43–4.73), with no signal of added harm.
A post-hoc analysis by Lázaro-Martínez and colleagues showed that benefit was greatest when treatment began early: among ulcers present two months or less at baseline, closure rates were 71% with the active dressing versus 41% with control, whereas wounds of longer duration healed less often in both arms. A Canadian economic evaluation by Wen and colleagues, modelling a public-payer perspective over five years, estimated the dressing to be both cost-saving and cost-effective, largely through reduced spending on persistent ulcer management and amputation.
Where These Products Fit
The 2023 IWGDF guideline on interventions to enhance healing issued 29 recommendations, and the supportive ones — for sucrose octasulfate dressings, placental-derived products, the autologous leucocyte/platelet/fibrin patch, negative pressure wound therapy in post-operative wounds, and oxygen therapies — are uniformly conditional. The guideline attaches two conditions consistently: these interventions are for wounds that best standard care has failed to heal on its own, and they should be used where resources permit. The panel explicitly noted that although the evidence base is improving, overall certainty remains poor, and called for better trials rather than more of them.
Clinical Summary
Across product classes, the pooled evidence points in the same direction: adding a skin substitute, placental allograft, or sucrose octasulfate dressing to good standard care modestly improves the probability of closure at 6 and 12 weeks. What the evidence does not establish is which product is best, how these therapies compare with one another, whether the gains persist beyond the trial window, or how they perform outside industry-sponsored settings. None of them substitutes for the fundamentals — pressure offloading, adequate debridement, infection management, and vascular assessment — and their measured benefit is defined relative to those fundamentals being delivered well. Early identification of the wound that is not progressing, rather than late escalation to an advanced product, appears to be where the greatest advantage lies.
References
- Chen P, Vilorio NC, Dhatariya K, et al. Guidelines on interventions to enhance healing of foot ulcers in people with diabetes (IWGDF 2023 update). Diabetes/Metabolism Research and Reviews. 2024;40(3):e3644.
- Santema TB, Poyck PPC, Ubbink DT. Skin grafting and tissue replacement for treating foot ulcers in people with diabetes. Cochrane Database of Systematic Reviews. 2016;2:CD011255.
- Gordon AJ, Alfonso AR, Nicholson J, Chiu ES. Evidence for healing diabetic foot ulcers with biologic skin substitutes: a systematic review and meta-analysis. Annals of Plastic Surgery. 2019;83(4S Suppl 1):S31–S44.
- Edmonds M, Lázaro-Martínez JL, Alfayate-García JM, et al. Sucrose octasulfate dressing versus control dressing in patients with neuroischaemic diabetic foot ulcers (Explorer): an international, multicentre, double-blind, randomised, controlled trial. The Lancet Diabetes & Endocrinology. 2018;6(3):186–196.
- Lázaro-Martínez JL, Edmonds M, Rayman G, et al. Optimal wound closure of diabetic foot ulcers with early initiation of TLC-NOSF treatment: post-hoc analysis of Explorer. Journal of Wound Care. 2019;28(6):358–367.
- Mohammed YA, Farouk HK, Gbreel MI, et al. Human amniotic membrane products for patients with diabetic foot ulcers. Do they help? A systematic review and meta-analysis. Journal of Foot and Ankle Research. 2022;15(1):71.
- Lakmal K, Basnayake O, Hettiarachchi D. Systematic review on the rational use of amniotic membrane allografts in diabetic foot ulcer treatment. BMC Surgery. 2021;21(1):87.
- Armstrong DG, Orgill DP, Galiano R, et al. A multicenter, randomized controlled clinical trial evaluating the effects of a novel autologous heterogeneous skin construct in the treatment of Wagner one diabetic foot ulcers: final analysis. International Wound Journal. 2023;20(10):4083–4096.
- Wen J, Jin X, Al Sayah F, Johnson JA, Paulden M, Ohinmaa A. Economic evaluation of sucrose octasulfate dressing for treatment of diabetic foot ulcers in patients with type 2 diabetes. Canadian Journal of Diabetes. 2022;46(2):126–133.
Comments
